SyntekaBio,Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name SyntekaBio,Inc.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 46.4%
- Equity ratio
- 68.3%
- ROE
- -54.7%
- Op. margin
- -313.9%
- Rev. growth
- 2,736.7%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 145.7% | 40.7% | -53.6% | -2,807.9% | n/a |
| FY2022 consolidated | 77.0% | 56.5% | -14.3% | -4,833.0% | -22.9% |
| FY2023 consolidated | 69.5% | 59.0% | -36.5% | -9,947.9% | -49.4% |
| FY2024 consolidated | 75.3% | 57.1% | -28.9% | -11,804.0% | -2.0% |
| FY2025 consolidated | 46.4% | 68.3% | -54.7% | -313.9% | 2,736.7% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩316.7M | ₩244.0M | ₩123.4M | ₩120.9M | ₩3.4B |
| Operating profit | -₩8.9B | -₩11.8B | -₩12.3B | -₩14.3B | -₩10.8B |
| Pre-tax income | -₩14.8B | -₩4.5B | -₩11.4B | -₩7.2B | -₩17.4B |
| Net income | -₩14.8B | -₩4.5B | -₩11.4B | -₩7.2B | -₩17.4B |
| Total assets | ₩67.9B | ₩55.7B | ₩52.9B | ₩43.7B | ₩46.5B |
| Total liabilities | ₩40.3B | ₩24.2B | ₩21.7B | ₩18.8B | ₩14.8B |
| Total equity | ₩27.6B | ₩31.5B | ₩31.2B | ₩24.9B | ₩31.8B |
| Paid-in capital | ₩6.8B | ₩6.8B | ₩7.6B | ₩7.6B | ₩12.1B |
| Debt/equity (source value) | 145.7% | 77.0% | 69.5% | 75.3% | 46.4% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2009-09-15
- Listed
- 19/12/17
- Employees
- 49
- Auditor
- n/a
- Audit opinion
- n/a
- Corporate reg. no.
- 1101114179457
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 신테카바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.